000148855 001__ 148855
000148855 005__ 20240229123037.0
000148855 0247_ $$2doi$$a10.3390/cancers12010073
000148855 0247_ $$2pmid$$apmid:31888022
000148855 0247_ $$2altmetric$$aaltmetric:96729078
000148855 037__ $$aDKFZ-2020-00047
000148855 041__ $$aeng
000148855 082__ $$a610
000148855 1001_ $$aDyberg, Cecilia$$b0
000148855 245__ $$aInhibition of Rho-Associated Kinase Suppresses Medulloblastoma Growth.
000148855 260__ $$aBasel$$bMDPI$$c2020
000148855 3367_ $$2DRIVER$$aarticle
000148855 3367_ $$2DataCite$$aOutput Types/Journal article
000148855 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1601533359_32562
000148855 3367_ $$2BibTeX$$aARTICLE
000148855 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000148855 3367_ $$00$$2EndNote$$aJournal Article
000148855 500__ $$aCancers 2020, 12(1), 73; https://doi.org/10.3390/cancers12010073
000148855 520__ $$aMedulloblastoma is one of the most common malignant brain tumor types in children, with an overall survival of 70%. Mortality is associated with metastatic relapsed tumors. Rho-associated kinases (ROCKs), important for epithelial-mesenchymal transition (EMT) and proper nervous system development, have previously been identified as a promising drug target to inhibit cancer growth and metastatic spread. Here, we show that ROCKs are expressed in medulloblastoma, with higher ROCK2 mRNA expression in metastatic compared to non-metastatic tumors. By evaluating three ROCK inhibitors in a panel of medulloblastoma cell lines we demonstrated that medulloblastoma cells were sensitive for pharmacological ROCK inhibition. The specific ROCK inhibitor RKI-1447 inhibited the tumorigenicity in medulloblastoma cells as well as impeded cell migration and invasion. Differential gene expression analysis suggested that ROCK inhibition was associated with the downregulation of signaling pathways important in proliferation and metastasis e.g., TNFα via NFκβ, TGFβ, and EMT. Expression of key proteins in these pathways such as RHOA, RHOB, JUN, and vimentin was downregulated in ROCK inhibited cells. Finally, we showed that ROCK inhibition by RKI-1447 suppressed medulloblastoma growth and proliferation in vivo. Collectively, our results suggest that ROCK inhibition presents a potential new therapeutic option in medulloblastoma, especially for children with metastatic disease.
000148855 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000148855 588__ $$aDataset connected to CrossRef, PubMed,
000148855 7001_ $$aAndonova, Teodora$$b1
000148855 7001_ $$aOlsen, Thale Kristin$$b2
000148855 7001_ $$aBrodin, Bertha$$b3
000148855 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b4$$udkfz
000148855 7001_ $$aKogner, Per$$b5
000148855 7001_ $$00000-0003-1277-812X$$aJohnsen, John Inge$$b6
000148855 7001_ $$aWickström, Malin$$b7
000148855 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers12010073$$gVol. 12, no. 1, p. 73 -$$n1$$p73$$tCancers$$v12$$x2072-6694$$y2020
000148855 909CO $$ooai:inrepo02.dkfz.de:148855$$pVDB
000148855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000148855 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000148855 9141_ $$y2020
000148855 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2017
000148855 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000148855 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000148855 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000148855 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000148855 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000148855 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000148855 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000148855 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000148855 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000148855 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000148855 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000148855 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000148855 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000148855 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000148855 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2017
000148855 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000148855 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000148855 980__ $$ajournal
000148855 980__ $$aVDB
000148855 980__ $$aI:(DE-He78)B062-20160331
000148855 980__ $$aI:(DE-He78)HD01-20160331
000148855 980__ $$aUNRESTRICTED